RE:RE:RE:RE:RE:RE:RE:Stay focused on the factsQuick note about neutropeniia. Patients that go on trials are patients who have had many cycles of chemo. These chemo cycle have a very bad effect on the patients' bone marrow. It is actually difficult to tell at this stage if any neutropenia is because of the current treatment or because of past treatments.
As someof you might know my wife is now on a different phase I cancer trial. Her blood work did not come out so well and the lead investigator had to argue with the sponsor to allow her to go on the trial because he sees these low blood counts all the time. My wife has had 19 cycles of chemo and yes of course it has had an effect on her bone marrow. The doctor told me that if they for these phase I trials they had to have perfect blood work then not many patients would actually be able to participate.
SPCEO1 wrote: I can't remember off the top of my head if they specifically said all was going smoothly but they certainly alluded to that being the case. But seeing neutropenia is what the phase 1a was looking for so seeing it would be normal. Basically a dose escalation study is trying to determine how much of a drug can be tolerated before trouble arises so finding things like neutrpenia is the goal of the study and seeing it is normal.
PWIB123 wrote: Did they actually say all went smoothly? I don't recall hearing that, especially considering they released and acknowledged the neutropenia. I do remember them saying that the things they were seeing were consistent with preclinical.
canadapiet wrote: And they lied again!!!!!!!
They said the P1a all went smoothly, just like in the preclinicals............!
Look at where we are now..........
How long are the "people in the know" saying that there is "HOPE" ?????
Well, let us all "HOPE" that in the near future (?????again....) we can set a new high !!
Momo25 - (3/23/2022 9:54:30 AM)
RE:RE:RE:Stay focused on the facts
I bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to now are very tiny, if not insignificant.
I averaged down many times and i am still a bit below 6$ and I took a hit of 49k by selling half of my THTX portfolio. Many shhareholders are in the same situation where I am. This is our reality today. The rest is bla..bla